Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Ellenberger

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
AAPS Pharmscitech|May 31, 2018
Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a ReviewDaniel J Ellenberger, Dave A Miller, Robert O Williams
AAPS Pharmscitech|June 6, 2018
Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir TabletDaniel J Ellenberger, Dave A Miller, Sandra U Kucera, et al.
AAPS Pharmscitech|March 16, 2018
Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® ProcessingDaniel J Ellenberger, Dave A Miller, Sandra U Kucera, et al.
Molecular Pharmaceutics|June 11, 2020
<i>In Vitro</i> and <i>In Vivo</i> Behaviors of KinetiSol and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer†Scott V Jermain, Michael B Lowinger, Daniel J Ellenberger, et al.
The Journal of Pharmacy and Pharmacology|October 11, 2015
Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavirDave A Miller, Justin M Keen, Chris Brough, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
AAPS Pharmscitech|May 31, 2018
Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a ReviewDaniel J Ellenberger, Dave A Miller, Robert O Williams
AAPS Pharmscitech|June 6, 2018
Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir TabletDaniel J Ellenberger, Dave A Miller, Sandra U Kucera, et al.
AAPS Pharmscitech|March 16, 2018
Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® ProcessingDaniel J Ellenberger, Dave A Miller, Sandra U Kucera, et al.
Molecular Pharmaceutics|June 11, 2020
<i>In Vitro</i> and <i>In Vivo</i> Behaviors of KinetiSol and Spray-Dried Amorphous Solid Dispersions of a Weakly Basic Drug and Ionic Polymer†Scott V Jermain, Michael B Lowinger, Daniel J Ellenberger, et al.
The Journal of Pharmacy and Pharmacology|October 11, 2015
Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavirDave A Miller, Justin M Keen, Chris Brough, et al.
Pageof 1